Literature DB >> 25794567

Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients.

Mariana Muñoz-Esquerre1, Daniel Huertas, Ignacio Escobar, Marta López-Sánchez, Rosa Penín, Victor Peinado, Joan Albert Barberà, María Molina-Molina, Frederic Manresa, Jordi Dorca, Salud Santos.   

Abstract

PURPOSE: Fibronectin (Fn) and tenascin-C (TnC) are two extracellular matrix proteins associated with remodeling changes. Fn and TnC gene and protein expression in lung tissue, including their predominant location in bronchial and pulmonary artery structures, have not yet been fully evaluated. The aim of the present study was to assess: (1) gene expression of Fn and TnC in lung samples from chronic obstructive pulmonary disease (COPD) and non-COPD subjects; and (2) protein content and location of Fn and TnC in both groups.
METHODS: Consecutive subjects requiring lung resection due to lung cancer surgery were included. Lung specimens were examined for gene expression by quantitative real-time PCR (values expressed as fold change ratio). The analysis of their protein content and location was performed by western blot and immunohistochemical studies, respectively. Patients were divided into two cohorts according to COPD status.
RESULTS: A total of 41 patients (20 with COPD and 21 without COPD) were included. An enhanced Fn gene expression was observed in the COPD group compared to the non-COPD group (4.73 ± 0.54 vs. 2.65 ± 0.57; P = 0.012), whereas no differences in gene TnC expression were observed (2.91 ± 0.44 vs. 2.60 ± 0.48; P = 0.633). No differences in lung protein content and location were found between groups. Immunohistochemical evaluation showed a predominantly vascular and bronchial location of Fn and TnC in both groups.
CONCLUSIONS: An enhanced lung gene expression of Fn was observed in COPD subjects compared to non-COPD subjects. No differences were found in Fn protein expression or in TnC gene or protein expression among groups.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25794567     DOI: 10.1007/s00408-015-9717-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  29 in total

1.  Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease.

Authors:  V I Peinado; J A Barberá; P Abate; J Ramírez; J Roca; S Santos; R Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  1999-05       Impact factor: 21.405

Review 2.  Tenascin-C in development and disease: gene regulation and cell function.

Authors:  P L Jones; F S Jones
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

Review 3.  Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth.

Authors:  Ellen Van Obberghen-Schilling; Richard P Tucker; Falk Saupe; Isabelle Gasser; Botond Cseh; Gertraud Orend
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

Review 4.  The role of tenascin C in cardiovascular disease.

Authors:  Jonathan Golledge; Paula Clancy; Jane Maguire; Lisa Lincz; Simon Koblar
Journal:  Cardiovasc Res       Date:  2011-06-28       Impact factor: 10.787

Review 5.  Tenascins.

Authors:  Ruth Chiquet-Ehrismann
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

6.  Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  John V Gosselink; Shizu Hayashi; W Mark Elliott; Li Xing; Becky Chan; Luojia Yang; Claire Wright; Don Sin; Peter D Paré; John A Pierce; Richard A Pierce; Alex Patterson; Joel Cooper; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2010-01-14       Impact factor: 21.405

7.  Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension.

Authors:  Julia Hoffmann; Jochen Wilhelm; Leigh M Marsh; Bahil Ghanim; Walter Klepetko; Gabor Kovacs; Horst Olschewski; Andrea Olschewski; Grazyna Kwapiszewska
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

8.  Opposite effect of fluticasone and salmeterol on fibronectin and tenascin-C expression in primary human lung fibroblasts.

Authors:  M Degen; S Goulet; J Ferralli; M Roth; M Tamm; R Chiquet-Ehrismann
Journal:  Clin Exp Allergy       Date:  2009-03-20       Impact factor: 5.018

9.  Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD.

Authors:  Magnus Löfdahl; Riitta Kaarteenaho; Elisa Lappi-Blanco; Göran Tornling; Magnus C Sköld
Journal:  Respir Res       Date:  2011-04-15

Review 10.  Advances in tenascin-C biology.

Authors:  Kim S Midwood; Thomas Hussenet; Benoit Langlois; Gertraud Orend
Journal:  Cell Mol Life Sci       Date:  2011-08-05       Impact factor: 9.261

View more
  1 in total

1.  Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.

Authors:  Florian Gebauer; Suyin Gelis; Hilke Zander; Karl-Frederick Meyer; Gerrit Wolters-Eisfeld; Jakob R Izbicki; Maximilian Bockhorn; Michael Tachezy
Journal:  Oncotarget       Date:  2016-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.